OTCPK:EVAR.F

Stock Analysis Report

Executive Summary

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Lombard Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-40.8%

EVAR.F

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

-73.6%

EVAR.F

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: EVAR.F underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: EVAR.F underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

EVAR.FIndustryMarket
7 Day-40.8%-0.003%1.3%
30 Day-17.1%-3.0%-1.9%
90 Dayn/a-0.6%-1.8%
1 Year-73.6%-73.6%12.8%11.9%8.3%5.9%
3 Year-99.7%-99.7%69.6%64.5%45.6%36.2%
5 Year-100.0%-100.0%129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is Lombard Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Lombard Medical undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Lombard Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lombard Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of EVAR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Lombard Medical regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Lombard Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lombard Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of EVAR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Lombard Medical's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Lombard Medical performed over the past 5 years?

17.0%

Historical Healthcare annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if EVAR.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare EVAR.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if EVAR.F's earnings growth over the past year exceeded the Medical Equipment industry average.


Return on Equity

High ROE: EVAR.F has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: Insufficient data to calculate EVAR.F's Return on Assets to determine if it is higher than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: Insufficient data to calculate EVAR.F's Return on Capital Employed to determine if it has improved over the past 3 years.


Next Steps

Financial Health

How is Lombard Medical's financial position?


In this section we usually analyse Lombard Medical's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Lombard Medical has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of EVAR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Lombard Medical's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Lombard Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate EVAR.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EVAR.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if EVAR.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVAR.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVAR.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Lombard Medical's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average board tenure


CEO

Kurt Lemvigh (51yo)

2.5yrs

Tenure

0

Mr. Kurt B. Lemvigh has been Chief Executive Officer of Lombard Medical, Inc. since April 20, 2017. Mr. Lemvigh has been Vice President for International Sales of Cardiac Science Corporation since Septembe ...


Board Age and Tenure

2.8yrs

Average Tenure

44yo

Average Age

Experienced Board: EVAR.F's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Kurt Lemvigh (51yo)

    Chief Executive Officer

    • Tenure: 2.5yrs
  • Peter Phillips (60yo)

    Chief Technology Officer

    • Tenure: 0yrs
    • Compensation: US$292.10k
  • Kate Forster

    Vice President of Human Resources

    • Tenure: 0yrs
  • Paul Hardwick

    Vice President of Sales

    • Tenure: 0yrs
  • Andrew Debbage

    Vice President of Operations

    • Tenure: 0yrs
  • Jonathan Hornsby

    Vice President of Sales & Marketing

    • Tenure: 2.1yrs

Board Members

  • Mike Carrel (48yo)

    Non-Executive Director

    • Tenure: 4.7yrs
    • Compensation: US$70.45k
  • Martin Sun (44yo)

    Non-Executive Director

    • Tenure: 2.8yrs
  • Jonathan Chen (44yo)

    Non-Executive Director

    • Tenure: 2.8yrs

Company Information

Lombard Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lombard Medical, Inc.
  • Ticker: EVAR.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$81.057k
  • Shares outstanding: 27.95m
  • Website: https://www.lombardmedical.com

Number of Employees


Location

  • Lombard Medical, Inc.
  • 4 Trident Park
  • Didcot
  • Oxfordshire
  • OX11 7HJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EVAR.FOTCPK (Pink Sheets LLC)YesNew Ordinary SharesUSUSDApr 2014

Biography

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:32
End of Day Share Price2019/10/11 00:00
Earnings2016/12/31
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.